British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
Effects of DMT on mental health outcomes in healthy volunteers
Scientific ReportsPsilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness ...
Christopher Timmermann +4 more
doaj +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Breaking Out of One’s Head (& Awakening to the World) [PDF]
, 2019 Herein, I review the shattering moment in my life when I awoke from the dream of self to find being as part of the living world and not in my head, discovering my perspectival center to be literally everywhere.
Nixon, Gregory
core
Insights into the pathogenesis of nicotine addiction. Could a salivary biosensor be useful in Nicotine Replacement Therapy (NRT)? [PDF]
, 2019 Nicotine has gained the attention of the medical community due to its insidious addictive mechanisms which lead to chronic consumption. The multitude of compounds derived from tobacco smoke have local and systemic negative impacts, resulting in a large ...
Alexescu, Teodora G +13 more
core +2 more sources
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)
Scientific ReportsThe Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs.
Richard J. Zeifman +7 more
doaj +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, EarlyView.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents [PDF]
, 2022 Alaina M. Jaster +5 more
openalex +1 more source